Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2011-5-23
pubmed:abstractText
To evaluate whether rescue with cord blood transplantation (CBT) could improve the poor survival after graft failure (GF), we surveyed the data of 80 adult patients (median age, 51 years) who received CBT within 3 months of GF (primary 64, secondary 16), with fludarabine-based reduced-intensity regimens with or without melphalan, busulfan, cyclophosphamide, and/or 2-4 Gy total-body irradiation (TBI). A median number of 2.4 × 10(7)/kg total nucleated cells (TNC) were infused, and among the 61 evaluable patients who survived for more than 28 days, 45 (74%) engrafted. The median follow-up of surviving patients was 325 days, and the 1-year overall survival rate was 33% despite poor performance status (2-4, 60%), carryover organ toxicities (grade 3/4, 14%), and infections (82%) prior to CBT. Day 100 transplantation-related mortality was 45%, with 60% related to infectious complications. Multivariate analysis showed that the infusion of TNC ?2.5 × 10(7)/kg and an alkylating agent-containing regimen were associated with a higher probability of engraftment, and that high risk-status at the preceding transplantation and grade 3/4 organ toxicities before CBT were associated with an increased risk of mortality. In conclusion, in an older population of patients, our data support the feasibility of CBT with a reduced-intensity conditioning regimen for GF.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1523-6536
pubmed:author
pubmed-author:EtoTetsuyaT, pubmed-author:FukudaTakahiroT, pubmed-author:HagiharaMakiM, pubmed-author:HatanakaKazuoK, pubmed-author:IidaHiroatsuH, pubmed-author:KandaYoshinobuY, pubmed-author:KasaiMasaharuM, pubmed-author:KawanoFumioF, pubmed-author:MaedaYoshinobuY, pubmed-author:MasuokaKazuhiroK, pubmed-author:MoriTakehikoT, pubmed-author:MurataMakotoM, pubmed-author:NagafujiKojiK, pubmed-author:NakagawaHitoshiH, pubmed-author:NakamaeMikaM, pubmed-author:NishiwakiKaichiK, pubmed-author:ShirafujiNaokiN, pubmed-author:TakahashiSatoshiS, pubmed-author:TakaueYoichiY, pubmed-author:TaniguchiShuichiS, pubmed-author:TaniwakiMasafumiM, pubmed-author:TogamiKatsuhiroK, pubmed-author:UchidaToshikiT, pubmed-author:UedaYasunoriY, pubmed-author:UtsunomiyaAtaeA, pubmed-author:WakeAtsushiA, pubmed-author:WakiFusakoF, pubmed-author:YakushijiKazuakiK, pubmed-author:YakushijinKimikazuK, pubmed-author:YamashitaTakuyaT
pubmed:copyrightInfo
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
841-51
pubmed:meshHeading
pubmed-meshheading:20849969-Adult, pubmed-meshheading:20849969-Busulfan, pubmed-meshheading:20849969-Cord Blood Stem Cell Transplantation, pubmed-meshheading:20849969-Cyclophosphamide, pubmed-meshheading:20849969-Disease-Free Survival, pubmed-meshheading:20849969-Female, pubmed-meshheading:20849969-Graft Rejection, pubmed-meshheading:20849969-Graft Survival, pubmed-meshheading:20849969-Graft vs Host Disease, pubmed-meshheading:20849969-Humans, pubmed-meshheading:20849969-Longitudinal Studies, pubmed-meshheading:20849969-Lymphocyte Count, pubmed-meshheading:20849969-Male, pubmed-meshheading:20849969-Melphalan, pubmed-meshheading:20849969-Multivariate Analysis, pubmed-meshheading:20849969-Salvage Therapy, pubmed-meshheading:20849969-Transplantation Conditioning, pubmed-meshheading:20849969-Treatment Outcome, pubmed-meshheading:20849969-Vidarabine
pubmed:year
2011
pubmed:articleTitle
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
pubmed:affiliation
Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't